C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share.
C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO).
The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May 4 closing price, when the companies announced the deal. The share price also represents a 41 percent premium above the average closing price of SenoRx shares in the 90 trading days running up to the announcement, according to a press release.
SenoRx develops devices for detecting and treating breast cancer. Its products include the EnCor breast biopsy system, Gel Mark breast tissue markers and Contura balloon catheter. The company’s revenue was $55.6 million in 2009.
C.R. Bard posted first-quarter sales of $650.8 million, up 9.1 percent compared with $596.4 million during the same period last year. In December 2009, it purchased the Salt Lake City-based hemodialysis catheter business of Spire Corp. (NSDQ:SPIR).
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
